As of Apr 20
| +1.44 / +1.83%|
The 17 analysts offering 12-month price forecasts for Sarepta Therapeutics Inc have a median target of 92.00, with a high estimate of 101.00 and a low estimate of 55.00. The median estimate represents a +15.01% increase from the last price of 79.99.
The current consensus among 18 polled investment analysts is to Buy stock in Sarepta Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.